NICE has approved semaglutide (Wegovy) for specific patient groups, but implementation varies by region due to service capacity and local integrated care board (ICB) decisions
In the future, innovation may focus on five key areas: long-acting formulations, oral delivery methods, multi-target combination therapies, and expanding the range of indications
Each condition was analysed in triplicate with 10 islets per replicate
At SkinnyRx, this assessment is reviewed by a licensed medical provider to help determine appropriate weight loss options based on your health history, symptoms, and goals.
3,4 In fact, one study found that hair thinning was reported in almost 7% of people taking high-dose oral semaglutide, compared to less than 1% on placebo
The risk is likely lower for patients who are already at or near their goal weight and switching for maintenance purposes, but nutritional vigilance remains essential